$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Citius Oncology, Inc. (CTOR)CTOR

Citius Oncology, Inc.

$0.99

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/20/2024: CTOR (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: 0%	Upturn Advisory Performance 1	Avg. Invested days: 0
Profits based on simulation	Stock Returns Performance 1	Last Close 11/20/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: 0%	Avg. Invested days: 0
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 116.23M USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 92966	Beta -
52 Weeks Range 0.93 - 40.50	Updated Date 10/20/2024

Company Size Small-Cap Stock	Market Capitalization 116.23M USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 92966	Beta -
52 Weeks Range 0.93 - 40.50	Updated Date 10/20/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value 116225599	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding 2000000	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value 116225599	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 2000000	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating -	Target Price -	Buy -
Strong Buy -	Hold -	Sell -
Strong Sell -

Rating -	Target Price -	Buy -	Strong Buy -
Hold -	Sell -	Strong Sell -

About Citius Oncology, Inc.

Exchange	NASDAQ	Headquaters	New York, NY, United States
IPO Launch date	2022-12-08	Chairman, CEO & President	Mr. Leonard L. Mazur
Sector	Healthcare	Website
Industry	Drug Manufacturers - Specialty & Generic	Full time employees	-
Headquaters	New York, NY, United States
Chairman, CEO & President	Mr. Leonard L. Mazur
Website
Website
Full time employees	-

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.